MBCC 2010 header

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

Roman Fabbricatore

November 2nd 2025

How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key

No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

Related Content

Ariana Pelosci

November 4th 2025

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Roman Fabbricatore

November 2nd 2025